Carvedilol (drug) to treat liver disease.
Not Applicable
- Conditions
- Health Condition 1: K769- Liver disease, unspecified
- Registration Number
- CTRI/2023/01/048912
- Lead Sponsor
- Institute of Liver and Biliary Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Cirrhosis with Acute Variceal Bleed
2.Childâ??s B and C cirrhosis (CTP <= 12)
3.Patients age between 18 to 75 years
Exclusion Criteria
1.Gastric variceal bleed
2.Bleeding related to coagulopathy
3.Other causes of portal hypertensive
bleeding.
4.Acute on chronic liver failure
5.Sepsis
6.Shock(persistence of hypotension)
7.Acute kidney injury ( >1.5 mg%)
8.Grade 3 Ascites
9.Hyponatremia (Na < 125 mEq/L)
10.Complete portal vein thrombosis
11.Hepatocellular carcinoma ( >3cm lesion)
12.Tumoral portal vein thrombosis
13.Chronic kidney disease
14.Coronary artery disease
15.Valvular heart disease
16.Sick sinus syndrome/ Pacemaker
17.Arrythmia
18.Uncontrolled hypothyroidism and
hyperthyroidism.
19.Pregnancy
20.Failure to give consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hemodynamic response in both groupsTimepoint: Day 5
- Secondary Outcome Measures
Name Time Method Adverse Effects in both groupsTimepoint: 6 weeks;Death in both groupsTimepoint: 6 weeks;Decompensation events at 6-weeks in both groupsTimepoint: 6 weeks;Rebleeding within 6-week in both groupsTimepoint: 6 weeks